Trial Profile
A Multi-center, Open-label, Single-arm, Phase 3b Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2018
Price :
$35
*
At a glance
- Drugs Macitentan (Primary)
- Indications Pulmonary arterial hypertension
- Focus Registrational; Therapeutic Use
- Acronyms SYMPHONY
- Sponsors Actelion Pharmaceuticals
- 05 Oct 2018 Status changed from active, no longer recruiting to completed.
- 26 Apr 2018 Results of psychometric validation of Pah-Sympact (n=278) published in the Chest
- 02 Nov 2016 Results of psychometric validation of Pah-Sympact (n=278) presented at the 19th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research